| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emergency Medicine | 72 | 2025 | 93 | 31.400 |
Why?
|
| Emergency Service, Hospital | 109 | 2025 | 252 | 24.860 |
Why?
|
| Ultrasonography | 65 | 2025 | 203 | 15.170 |
Why?
|
| Point-of-Care Systems | 37 | 2025 | 58 | 14.940 |
Why?
|
| Humans | 405 | 2025 | 22823 | 14.750 |
Why?
|
| Internship and Residency | 32 | 2025 | 196 | 12.990 |
Why?
|
| Intubation, Intratracheal | 20 | 2025 | 82 | 9.880 |
Why?
|
| Heart Arrest | 15 | 2025 | 39 | 9.510 |
Why?
|
| Anti-Bacterial Agents | 24 | 2025 | 362 | 6.920 |
Why?
|
| Trachea | 14 | 2025 | 38 | 6.850 |
Why?
|
| Shoulder Dislocation | 12 | 2023 | 87 | 6.370 |
Why?
|
| Ultrasonography, Interventional | 12 | 2025 | 64 | 5.350 |
Why?
|
| Abscess | 10 | 2024 | 26 | 5.150 |
Why?
|
| Coronavirus Infections | 10 | 2020 | 74 | 4.990 |
Why?
|
| Cardiopulmonary Resuscitation | 10 | 2025 | 18 | 4.990 |
Why?
|
| Pneumonia, Viral | 10 | 2020 | 77 | 4.980 |
Why?
|
| Pulmonary Edema | 7 | 2025 | 21 | 4.830 |
Why?
|
| Pandemics | 23 | 2025 | 201 | 4.720 |
Why?
|
| Esophagus | 12 | 2023 | 53 | 4.590 |
Why?
|
| Education, Medical | 15 | 2023 | 41 | 4.570 |
Why?
|
| Joint Dislocations | 7 | 2022 | 50 | 4.530 |
Why?
|
| Stroke | 8 | 2023 | 241 | 4.440 |
Why?
|
| Point-of-Care Testing | 13 | 2023 | 26 | 4.080 |
Why?
|
| Venous Thrombosis | 6 | 2023 | 39 | 3.980 |
Why?
|
| Catheterization, Peripheral | 7 | 2023 | 15 | 3.960 |
Why?
|
| Physician Executives | 6 | 2023 | 8 | 3.910 |
Why?
|
| Pulmonary Embolism | 6 | 2024 | 55 | 3.800 |
Why?
|
| Shock, Septic | 6 | 2025 | 25 | 3.450 |
Why?
|
| Critical Illness | 9 | 2021 | 97 | 3.360 |
Why?
|
| Adult | 56 | 2025 | 6896 | 3.350 |
Why?
|
| Soft Tissue Infections | 7 | 2024 | 25 | 3.280 |
Why?
|
| Faculty, Medical | 14 | 2023 | 42 | 3.130 |
Why?
|
| Pneumonia | 5 | 2023 | 61 | 3.120 |
Why?
|
| Heart Failure | 6 | 2025 | 141 | 2.820 |
Why?
|
| Diabetic Ketoacidosis | 4 | 2022 | 5 | 2.820 |
Why?
|
| Brain Ischemia | 4 | 2022 | 61 | 2.800 |
Why?
|
| Thrombolytic Therapy | 6 | 2025 | 44 | 2.800 |
Why?
|
| Fluid Therapy | 11 | 2025 | 19 | 2.760 |
Why?
|
| Betacoronavirus | 6 | 2020 | 64 | 2.760 |
Why?
|
| Sensitivity and Specificity | 20 | 2025 | 439 | 2.750 |
Why?
|
| Artificial Intelligence | 4 | 2025 | 22 | 2.720 |
Why?
|
| Tranexamic Acid | 4 | 2022 | 17 | 2.690 |
Why?
|
| Prospective Studies | 25 | 2025 | 1487 | 2.650 |
Why?
|
| Compartment Syndromes | 4 | 2023 | 7 | 2.620 |
Why?
|
| Foreign Bodies | 5 | 2023 | 20 | 2.580 |
Why?
|
| Social Media | 7 | 2022 | 45 | 2.570 |
Why?
|
| Community-Acquired Infections | 4 | 2023 | 57 | 2.560 |
Why?
|
| Airway Management | 6 | 2021 | 14 | 2.480 |
Why?
|
| United States | 27 | 2025 | 1762 | 2.480 |
Why?
|
| Female | 53 | 2025 | 12904 | 2.470 |
Why?
|
| Fibrinolytic Agents | 6 | 2025 | 57 | 2.450 |
Why?
|
| Extracorporeal Membrane Oxygenation | 5 | 2025 | 20 | 2.440 |
Why?
|
| Myocardial Infarction | 4 | 2025 | 125 | 2.430 |
Why?
|
| Atrial Fibrillation | 5 | 2023 | 97 | 2.410 |
Why?
|
| Respiration, Artificial | 8 | 2025 | 84 | 2.360 |
Why?
|
| Child | 19 | 2023 | 1153 | 2.350 |
Why?
|
| Male | 50 | 2025 | 12400 | 2.320 |
Why?
|
| Telemedicine | 5 | 2025 | 84 | 2.310 |
Why?
|
| Nerve Block | 5 | 2025 | 61 | 2.310 |
Why?
|
| Sepsis | 4 | 2025 | 75 | 2.300 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 4 | 2023 | 7 | 2.270 |
Why?
|
| Skin Diseases | 4 | 2025 | 21 | 2.210 |
Why?
|
| Treatment Outcome | 21 | 2023 | 2934 | 2.180 |
Why?
|
| Adrenal Cortex Hormones | 12 | 2023 | 95 | 2.180 |
Why?
|
| Acute Disease | 15 | 2025 | 162 | 2.130 |
Why?
|
| Intussusception | 3 | 2022 | 3 | 2.130 |
Why?
|
| Anticoagulants | 10 | 2023 | 82 | 2.120 |
Why?
|
| Fractures, Bone | 4 | 2022 | 70 | 2.110 |
Why?
|
| Randomized Controlled Trials as Topic | 16 | 2025 | 243 | 2.110 |
Why?
|
| Pain | 5 | 2021 | 326 | 2.100 |
Why?
|
| Lung | 6 | 2025 | 138 | 2.090 |
Why?
|
| Teaching | 4 | 2022 | 46 | 2.070 |
Why?
|
| Intestinal Obstruction | 3 | 2023 | 11 | 2.040 |
Why?
|
| Respiratory Insufficiency | 5 | 2025 | 43 | 2.040 |
Why?
|
| Publishing | 11 | 2020 | 29 | 2.020 |
Why?
|
| Thrombosis | 3 | 2022 | 51 | 2.010 |
Why?
|
| Antifibrinolytic Agents | 3 | 2022 | 16 | 1.960 |
Why?
|
| Hospitalization | 7 | 2025 | 285 | 1.960 |
Why?
|
| Diverticulitis | 3 | 2025 | 6 | 1.950 |
Why?
|
| Endovascular Procedures | 3 | 2025 | 27 | 1.950 |
Why?
|
| Hospital Mortality | 4 | 2025 | 129 | 1.900 |
Why?
|
| Middle Aged | 32 | 2025 | 7873 | 1.900 |
Why?
|
| Drainage | 9 | 2025 | 36 | 1.880 |
Why?
|
| Epinephrine | 6 | 2025 | 29 | 1.830 |
Why?
|
| Disease Management | 6 | 2020 | 98 | 1.820 |
Why?
|
| Retrospective Studies | 23 | 2025 | 2976 | 1.810 |
Why?
|
| Low Back Pain | 3 | 2023 | 128 | 1.720 |
Why?
|
| Students, Medical | 4 | 2025 | 48 | 1.710 |
Why?
|
| Practice Guidelines as Topic | 9 | 2025 | 235 | 1.690 |
Why?
|
| Periodicals as Topic | 3 | 2025 | 31 | 1.620 |
Why?
|
| Congresses as Topic | 4 | 2020 | 30 | 1.570 |
Why?
|
| Peritonitis | 2 | 2023 | 17 | 1.560 |
Why?
|
| Manipulation, Orthopedic | 4 | 2023 | 7 | 1.550 |
Why?
|
| Risk Assessment | 12 | 2025 | 546 | 1.540 |
Why?
|
| Epistaxis | 3 | 2022 | 8 | 1.540 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2025 | 69 | 1.530 |
Why?
|
| Emergencies | 5 | 2021 | 27 | 1.530 |
Why?
|
| Diagnosis, Differential | 12 | 2024 | 309 | 1.520 |
Why?
|
| Emergency Medical Services | 4 | 2022 | 29 | 1.510 |
Why?
|
| Vomiting | 4 | 2025 | 18 | 1.500 |
Why?
|
| Electrocardiography | 7 | 2025 | 92 | 1.500 |
Why?
|
| Severe Acute Respiratory Syndrome | 3 | 2020 | 4 | 1.500 |
Why?
|
| Pain Management | 5 | 2020 | 126 | 1.470 |
Why?
|
| Catheters | 4 | 2025 | 15 | 1.460 |
Why?
|
| Thrombectomy | 4 | 2025 | 30 | 1.450 |
Why?
|
| Blood Coagulation Factors | 3 | 2023 | 19 | 1.440 |
Why?
|
| Dyspnea | 4 | 2025 | 35 | 1.440 |
Why?
|
| Thrombocytopenia | 2 | 2022 | 21 | 1.430 |
Why?
|
| Ventricular Fibrillation | 3 | 2020 | 13 | 1.430 |
Why?
|
| Thoracostomy | 2 | 2025 | 2 | 1.420 |
Why?
|
| Postthrombotic Syndrome | 2 | 2021 | 2 | 1.410 |
Why?
|
| Chest Tubes | 2 | 2025 | 4 | 1.410 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2022 | 38 | 1.410 |
Why?
|
| Health Personnel | 6 | 2025 | 81 | 1.410 |
Why?
|
| Diarrhea | 2 | 2021 | 31 | 1.410 |
Why?
|
| Probiotics | 2 | 2021 | 15 | 1.410 |
Why?
|
| Feedback | 4 | 2024 | 33 | 1.400 |
Why?
|
| Bibliometrics | 4 | 2025 | 22 | 1.390 |
Why?
|
| Rhabdomyolysis | 2 | 2023 | 5 | 1.390 |
Why?
|
| Anaphylaxis | 2 | 2021 | 11 | 1.390 |
Why?
|
| Acidosis | 2 | 2021 | 4 | 1.390 |
Why?
|
| Pancreatitis | 2 | 2023 | 20 | 1.380 |
Why?
|
| Clinical Competence | 10 | 2025 | 189 | 1.380 |
Why?
|
| Resuscitation | 5 | 2025 | 10 | 1.370 |
Why?
|
| Noninvasive Ventilation | 2 | 2021 | 11 | 1.360 |
Why?
|
| Neoplasms | 3 | 2023 | 215 | 1.340 |
Why?
|
| Balloon Occlusion | 2 | 2022 | 8 | 1.340 |
Why?
|
| Echocardiography | 5 | 2024 | 67 | 1.330 |
Why?
|
| Decompression, Surgical | 3 | 2021 | 117 | 1.320 |
Why?
|
| Anxiety Disorders | 2 | 2023 | 163 | 1.310 |
Why?
|
| Eye | 3 | 2022 | 6 | 1.310 |
Why?
|
| Hematoma | 2 | 2024 | 18 | 1.310 |
Why?
|
| Infusions, Intravenous | 5 | 2022 | 49 | 1.300 |
Why?
|
| Tachycardia, Ventricular | 2 | 2020 | 20 | 1.270 |
Why?
|
| Spinal Puncture | 2 | 2021 | 23 | 1.270 |
Why?
|
| Shoulder Fractures | 3 | 2020 | 28 | 1.270 |
Why?
|
| Tuberculosis | 2 | 2020 | 18 | 1.260 |
Why?
|
| Fever | 7 | 2023 | 32 | 1.250 |
Why?
|
| Research Design | 4 | 2025 | 157 | 1.240 |
Why?
|
| Risk Factors | 14 | 2025 | 1966 | 1.240 |
Why?
|
| Hip Dislocation | 2 | 2022 | 48 | 1.240 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2020 | 16 | 1.230 |
Why?
|
| Burnout, Professional | 2 | 2020 | 26 | 1.230 |
Why?
|
| Pharyngitis | 2 | 2020 | 7 | 1.230 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2020 | 86 | 1.230 |
Why?
|
| Intestine, Small | 2 | 2021 | 30 | 1.220 |
Why?
|
| Hip Fractures | 2 | 2021 | 23 | 1.220 |
Why?
|
| Oxygen | 2 | 2020 | 54 | 1.210 |
Why?
|
| Glucagon | 2 | 2019 | 6 | 1.210 |
Why?
|
| Appendicitis | 2 | 2021 | 15 | 1.200 |
Why?
|
| Acute Pain | 2 | 2020 | 22 | 1.200 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2024 | 572 | 1.190 |
Why?
|
| Communication | 5 | 2023 | 96 | 1.190 |
Why?
|
| Acetaminophen | 2 | 2021 | 22 | 1.190 |
Why?
|
| Curriculum | 8 | 2022 | 125 | 1.180 |
Why?
|
| Staff Development | 8 | 2019 | 17 | 1.160 |
Why?
|
| Inappropriate Prescribing | 2 | 2020 | 5 | 1.160 |
Why?
|
| Unnecessary Procedures | 2 | 2021 | 25 | 1.160 |
Why?
|
| Arthritis, Infectious | 2 | 2019 | 47 | 1.140 |
Why?
|
| Education, Medical, Graduate | 8 | 2023 | 67 | 1.140 |
Why?
|
| Capnography | 3 | 2018 | 8 | 1.140 |
Why?
|
| Time Factors | 10 | 2022 | 1258 | 1.140 |
Why?
|
| Arrhythmias, Cardiac | 4 | 2020 | 57 | 1.110 |
Why?
|
| Cadaver | 8 | 2022 | 281 | 1.080 |
Why?
|
| Skin Diseases, Infectious | 2 | 2018 | 6 | 1.070 |
Why?
|
| Antiviral Agents | 4 | 2022 | 66 | 1.040 |
Why?
|
| Aged | 17 | 2025 | 7412 | 1.030 |
Why?
|
| Leadership | 5 | 2022 | 78 | 1.030 |
Why?
|
| Cross-Sectional Studies | 8 | 2025 | 759 | 1.030 |
Why?
|
| Infant | 7 | 2022 | 478 | 1.010 |
Why?
|
| Pneumothorax | 2 | 2025 | 4 | 1.010 |
Why?
|
| Anesthetics, Local | 7 | 2025 | 71 | 1.010 |
Why?
|
| Physicians | 4 | 2022 | 104 | 1.010 |
Why?
|
| Asthma | 2 | 2020 | 152 | 1.000 |
Why?
|
| Evidence-Based Medicine | 5 | 2021 | 137 | 1.000 |
Why?
|
| Acute Kidney Injury | 2 | 2024 | 33 | 1.000 |
Why?
|
| Machine Learning | 2 | 2025 | 59 | 0.990 |
Why?
|
| Antiemetics | 2 | 2025 | 10 | 0.970 |
Why?
|
| Gonorrhea | 2 | 2023 | 5 | 0.970 |
Why?
|
| Vasoconstrictor Agents | 3 | 2025 | 19 | 0.970 |
Why?
|
| Chlamydia Infections | 2 | 2023 | 5 | 0.970 |
Why?
|
| Fasciitis, Necrotizing | 2 | 2022 | 3 | 0.970 |
Why?
|
| Self Concept | 2 | 2023 | 37 | 0.950 |
Why?
|
| Analgesia | 2 | 2017 | 34 | 0.940 |
Why?
|
| Journal Impact Factor | 2 | 2025 | 13 | 0.940 |
Why?
|
| Gastroparesis | 1 | 2025 | 3 | 0.930 |
Why?
|
| Cannabinoids | 1 | 2025 | 3 | 0.930 |
Why?
|
| Multiple Chronic Conditions | 1 | 2025 | 8 | 0.930 |
Why?
|
| Catheterization | 1 | 2025 | 40 | 0.920 |
Why?
|
| Automobile Driving | 2 | 2025 | 17 | 0.920 |
Why?
|
| Educational Measurement | 2 | 2025 | 53 | 0.910 |
Why?
|
| Skin | 3 | 2021 | 118 | 0.910 |
Why?
|
| Correspondence as Topic | 1 | 2025 | 2 | 0.900 |
Why?
|
| Clinical Clerkship | 1 | 2025 | 26 | 0.880 |
Why?
|
| Ear Auricle | 1 | 2024 | 1 | 0.880 |
Why?
|
| Peer Review | 3 | 2022 | 4 | 0.880 |
Why?
|
| Gender Identity | 1 | 2024 | 20 | 0.880 |
Why?
|
| Phenytoin | 2 | 2021 | 5 | 0.870 |
Why?
|
| Status Epilepticus | 2 | 2021 | 12 | 0.860 |
Why?
|
| Myocarditis | 2 | 2021 | 9 | 0.860 |
Why?
|
| Critical Care | 3 | 2022 | 97 | 0.850 |
Why?
|
| Triage | 3 | 2021 | 18 | 0.850 |
Why?
|
| Ketamine | 2 | 2021 | 23 | 0.840 |
Why?
|
| Competency-Based Education | 2 | 2021 | 10 | 0.840 |
Why?
|
| Intensive Care Units | 3 | 2021 | 234 | 0.840 |
Why?
|
| Diverticulitis, Colonic | 1 | 2023 | 3 | 0.830 |
Why?
|
| Nystagmus, Pathologic | 1 | 2023 | 2 | 0.830 |
Why?
|
| Anticonvulsants | 3 | 2021 | 51 | 0.830 |
Why?
|
| Anti-Arrhythmia Agents | 5 | 2025 | 27 | 0.830 |
Why?
|
| Larynx | 2 | 2023 | 10 | 0.830 |
Why?
|
| Cultural Diversity | 2 | 2021 | 20 | 0.830 |
Why?
|
| Dizziness | 1 | 2023 | 17 | 0.830 |
Why?
|
| Laryngeal Masks | 1 | 2023 | 5 | 0.820 |
Why?
|
| Education, Medical, Continuing | 3 | 2021 | 29 | 0.820 |
Why?
|
| Trichomonas vaginalis | 1 | 2023 | 3 | 0.820 |
Why?
|
| Medical Errors | 2 | 2020 | 25 | 0.820 |
Why?
|
| Fellowships and Scholarships | 3 | 2022 | 34 | 0.820 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2021 | 38 | 0.820 |
Why?
|
| Intracranial Hemorrhages | 2 | 2025 | 11 | 0.820 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2023 | 12 | 0.810 |
Why?
|
| Algorithms | 6 | 2025 | 295 | 0.810 |
Why?
|
| Cerebral Hemorrhage | 2 | 2022 | 103 | 0.810 |
Why?
|
| Bites and Stings | 2 | 2020 | 3 | 0.810 |
Why?
|
| Sex Distribution | 2 | 2020 | 64 | 0.810 |
Why?
|
| Hypothermia, Induced | 1 | 2023 | 15 | 0.810 |
Why?
|
| Patient Selection | 2 | 2021 | 166 | 0.800 |
Why?
|
| Crush Syndrome | 1 | 2023 | 1 | 0.800 |
Why?
|
| Mass Casualty Incidents | 1 | 2023 | 4 | 0.800 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2020 | 17 | 0.800 |
Why?
|
| Incidence | 5 | 2025 | 624 | 0.800 |
Why?
|
| Peritonsillar Abscess | 1 | 2023 | 2 | 0.790 |
Why?
|
| Factor Xa Inhibitors | 1 | 2023 | 4 | 0.790 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2020 | 26 | 0.790 |
Why?
|
| Venous Thromboembolism | 1 | 2023 | 32 | 0.780 |
Why?
|
| Catheterization, Central Venous | 1 | 2023 | 34 | 0.780 |
Why?
|
| Conjunctivitis, Bacterial | 1 | 2022 | 2 | 0.780 |
Why?
|
| Heart | 1 | 2023 | 59 | 0.770 |
Why?
|
| Magnesium Sulfate | 1 | 2022 | 5 | 0.770 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2022 | 8 | 0.770 |
Why?
|
| Abortion, Induced | 1 | 2022 | 7 | 0.770 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2022 | 4 | 0.770 |
Why?
|
| Anesthesia | 1 | 2023 | 28 | 0.770 |
Why?
|
| Cellulitis | 5 | 2024 | 10 | 0.760 |
Why?
|
| Temporomandibular Joint Disorders | 1 | 2022 | 7 | 0.760 |
Why?
|
| Clostridium Infections | 1 | 2022 | 24 | 0.760 |
Why?
|
| Biomedical Research | 2 | 2025 | 51 | 0.760 |
Why?
|
| Shoulder | 2 | 2020 | 144 | 0.750 |
Why?
|
| Cerebral Veins | 1 | 2022 | 5 | 0.750 |
Why?
|
| Faculty | 2 | 2019 | 24 | 0.750 |
Why?
|
| Vancomycin | 1 | 2022 | 51 | 0.750 |
Why?
|
| Pregnancy, Interstitial | 1 | 2022 | 1 | 0.750 |
Why?
|
| Edema | 2 | 2019 | 22 | 0.750 |
Why?
|
| Uterine Rupture | 1 | 2022 | 3 | 0.750 |
Why?
|
| Vaccines | 1 | 2022 | 7 | 0.750 |
Why?
|
| Bacterial Infections | 1 | 2022 | 47 | 0.740 |
Why?
|
| Drug Hypersensitivity Syndrome | 1 | 2022 | 3 | 0.740 |
Why?
|
| Azithromycin | 1 | 2022 | 2 | 0.740 |
Why?
|
| Airway Obstruction | 2 | 2019 | 16 | 0.740 |
Why?
|
| Torsades de Pointes | 1 | 2022 | 5 | 0.730 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2022 | 3 | 0.730 |
Why?
|
| Long QT Syndrome | 1 | 2022 | 5 | 0.730 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 42 | 0.730 |
Why?
|
| Gout | 1 | 2021 | 5 | 0.730 |
Why?
|
| Neuroimaging | 1 | 2022 | 100 | 0.730 |
Why?
|
| Colchicine | 1 | 2021 | 10 | 0.730 |
Why?
|
| Sympathomimetics | 1 | 2021 | 5 | 0.730 |
Why?
|
| Eosinophilia | 1 | 2022 | 35 | 0.730 |
Why?
|
| Ketosis | 1 | 2021 | 7 | 0.720 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 103 | 0.720 |
Why?
|
| Droperidol | 2 | 2022 | 7 | 0.720 |
Why?
|
| Exanthema | 4 | 2023 | 10 | 0.720 |
Why?
|
| Helicobacter Infections | 1 | 2021 | 2 | 0.720 |
Why?
|
| Anemia, Hemolytic | 1 | 2021 | 4 | 0.720 |
Why?
|
| Sternoclavicular Joint | 1 | 2021 | 4 | 0.720 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 4 | 0.720 |
Why?
|
| Polyradiculopathy | 1 | 2021 | 2 | 0.710 |
Why?
|
| Arm Injuries | 1 | 2021 | 7 | 0.710 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2021 | 9 | 0.710 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 16 | 0.710 |
Why?
|
| Dexmedetomidine | 1 | 2021 | 5 | 0.710 |
Why?
|
| Hyperglycemic Hyperosmolar Nonketotic Coma | 1 | 2021 | 1 | 0.710 |
Why?
|
| Kounis Syndrome | 1 | 2021 | 1 | 0.710 |
Why?
|
| Cardiology | 1 | 2022 | 44 | 0.700 |
Why?
|
| Streptococcal Infections | 2 | 2018 | 9 | 0.700 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 8 | 0.700 |
Why?
|
| Ibuprofen | 1 | 2021 | 9 | 0.700 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2021 | 9 | 0.690 |
Why?
|
| Heart-Assist Devices | 1 | 2021 | 18 | 0.690 |
Why?
|
| Physicians, Family | 1 | 2021 | 4 | 0.690 |
Why?
|
| Giant Cell Arteritis | 1 | 2021 | 2 | 0.690 |
Why?
|
| Patient Safety | 2 | 2020 | 34 | 0.690 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 27 | 0.690 |
Why?
|
| Psychomotor Agitation | 2 | 2018 | 10 | 0.690 |
Why?
|
| Ambulatory Care | 1 | 2021 | 66 | 0.690 |
Why?
|
| Alcoholism | 1 | 2021 | 64 | 0.690 |
Why?
|
| Comprehension | 1 | 2021 | 25 | 0.690 |
Why?
|
| Patient Satisfaction | 3 | 2020 | 255 | 0.690 |
Why?
|
| Program Development | 1 | 2021 | 44 | 0.680 |
Why?
|
| Ischemic Attack, Transient | 1 | 2021 | 16 | 0.680 |
Why?
|
| Blister | 1 | 2020 | 1 | 0.680 |
Why?
|
| Adolescent | 8 | 2025 | 1874 | 0.680 |
Why?
|
| Mental Disorders | 1 | 2022 | 134 | 0.680 |
Why?
|
| Elbow Joint | 1 | 2022 | 113 | 0.680 |
Why?
|
| Secondary Prevention | 1 | 2021 | 48 | 0.680 |
Why?
|
| Heart Transplantation | 1 | 2021 | 30 | 0.670 |
Why?
|
| Patient Care Management | 1 | 2020 | 15 | 0.670 |
Why?
|
| Memory, Short-Term | 1 | 2021 | 79 | 0.670 |
Why?
|
| Burns | 1 | 2020 | 15 | 0.670 |
Why?
|
| Hypertension | 1 | 2022 | 163 | 0.670 |
Why?
|
| Drug Therapy | 1 | 2020 | 5 | 0.670 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 5 | 0.670 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 7 | 0.670 |
Why?
|
| Writing | 3 | 2022 | 16 | 0.670 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2020 | 14 | 0.670 |
Why?
|
| Bronchoscopy | 3 | 2023 | 31 | 0.670 |
Why?
|
| Allied Health Personnel | 1 | 2020 | 7 | 0.670 |
Why?
|
| Alanine | 1 | 2020 | 12 | 0.670 |
Why?
|
| Fracture Healing | 1 | 2020 | 32 | 0.660 |
Why?
|
| Physical Examination | 4 | 2022 | 87 | 0.660 |
Why?
|
| Debridement | 1 | 2020 | 66 | 0.660 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 15 | 0.660 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 15 | 0.660 |
Why?
|
| Documentation | 1 | 2020 | 20 | 0.660 |
Why?
|
| Wound Infection | 1 | 2020 | 6 | 0.660 |
Why?
|
| Hypotension | 2 | 2018 | 20 | 0.660 |
Why?
|
| Sleep Deprivation | 1 | 2020 | 35 | 0.660 |
Why?
|
| Work Schedule Tolerance | 1 | 2020 | 23 | 0.660 |
Why?
|
| Nurses | 1 | 2021 | 41 | 0.650 |
Why?
|
| Problem Solving | 1 | 2020 | 38 | 0.650 |
Why?
|
| Sulfonamides | 2 | 2021 | 45 | 0.650 |
Why?
|
| Spleen | 1 | 2020 | 28 | 0.640 |
Why?
|
| Arthrocentesis | 1 | 2020 | 2 | 0.640 |
Why?
|
| Defibrillators, Implantable | 1 | 2020 | 10 | 0.640 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2020 | 46 | 0.640 |
Why?
|
| Mass Screening | 1 | 2021 | 159 | 0.640 |
Why?
|
| Young Adult | 8 | 2025 | 1647 | 0.640 |
Why?
|
| Intra-Abdominal Hypertension | 1 | 2019 | 3 | 0.630 |
Why?
|
| Prochlorperazine | 1 | 2019 | 1 | 0.630 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 56 | 0.630 |
Why?
|
| Pregnancy | 4 | 2022 | 324 | 0.630 |
Why?
|
| Education, Continuing | 1 | 2020 | 9 | 0.630 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 112 | 0.630 |
Why?
|
| Chorionic Gonadotropin | 2 | 2017 | 16 | 0.630 |
Why?
|
| Arteries | 2 | 2017 | 13 | 0.630 |
Why?
|
| Administration, Oral | 4 | 2023 | 97 | 0.620 |
Why?
|
| Review Literature as Topic | 2 | 2023 | 9 | 0.620 |
Why?
|
| Migraine Disorders | 1 | 2019 | 18 | 0.620 |
Why?
|
| Formative Feedback | 1 | 2019 | 3 | 0.620 |
Why?
|
| Angioedema | 1 | 2019 | 2 | 0.620 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2019 | 17 | 0.610 |
Why?
|
| Quality Improvement | 1 | 2020 | 128 | 0.610 |
Why?
|
| Hair | 1 | 2019 | 3 | 0.610 |
Why?
|
| Tourniquets | 1 | 2019 | 4 | 0.610 |
Why?
|
| Vasopressins | 3 | 2025 | 7 | 0.610 |
Why?
|
| Abdominal Injuries | 1 | 2019 | 3 | 0.610 |
Why?
|
| Ischemia | 1 | 2019 | 22 | 0.600 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2019 | 6 | 0.600 |
Why?
|
| Transducers | 1 | 2019 | 10 | 0.600 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 133 | 0.600 |
Why?
|
| Gastrointestinal Agents | 1 | 2019 | 9 | 0.600 |
Why?
|
| Aorta | 1 | 2019 | 16 | 0.600 |
Why?
|
| Influenza, Human | 1 | 2019 | 40 | 0.600 |
Why?
|
| Forearm Injuries | 1 | 2019 | 5 | 0.600 |
Why?
|
| Retinal Detachment | 1 | 2019 | 7 | 0.600 |
Why?
|
| Craniocerebral Trauma | 1 | 2018 | 5 | 0.600 |
Why?
|
| Emergency Treatment | 1 | 2018 | 3 | 0.590 |
Why?
|
| Radius | 1 | 2019 | 32 | 0.590 |
Why?
|
| Training Support | 1 | 2018 | 4 | 0.590 |
Why?
|
| Research Support as Topic | 1 | 2018 | 12 | 0.590 |
Why?
|
| Nausea | 3 | 2023 | 24 | 0.580 |
Why?
|
| Publications | 4 | 2022 | 13 | 0.580 |
Why?
|
| Length of Stay | 4 | 2025 | 298 | 0.570 |
Why?
|
| Rocky Mountain Spotted Fever | 1 | 2018 | 1 | 0.570 |
Why?
|
| Aortic Aneurysm | 1 | 2018 | 10 | 0.570 |
Why?
|
| Sleep | 1 | 2020 | 267 | 0.560 |
Why?
|
| Postoperative Complications | 2 | 2021 | 810 | 0.560 |
Why?
|
| Platelet Transfusion | 1 | 2018 | 6 | 0.560 |
Why?
|
| Authorship | 5 | 2022 | 11 | 0.560 |
Why?
|
| Closed Fracture Reduction | 1 | 2018 | 1 | 0.560 |
Why?
|
| Urolithiasis | 1 | 2018 | 1 | 0.560 |
Why?
|
| Cohort Studies | 9 | 2024 | 1412 | 0.560 |
Why?
|
| Ketorolac | 1 | 2018 | 12 | 0.560 |
Why?
|
| Traction | 1 | 2018 | 26 | 0.550 |
Why?
|
| Aortic Valve Stenosis | 1 | 2018 | 18 | 0.550 |
Why?
|
| Jugular Veins | 1 | 2017 | 1 | 0.550 |
Why?
|
| Longitudinal Studies | 6 | 2025 | 1047 | 0.550 |
Why?
|
| Coronary Sinus | 1 | 2017 | 2 | 0.540 |
Why?
|
| Seizures | 2 | 2020 | 62 | 0.530 |
Why?
|
| Cholinergic Antagonists | 1 | 2017 | 6 | 0.530 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2017 | 2 | 0.530 |
Why?
|
| Bronchiectasis | 1 | 2017 | 1 | 0.530 |
Why?
|
| Cough | 1 | 2017 | 8 | 0.520 |
Why?
|
| Psychotic Disorders | 1 | 2017 | 29 | 0.520 |
Why?
|
| Off-Label Use | 1 | 2017 | 6 | 0.520 |
Why?
|
| Calcium Channel Blockers | 2 | 2022 | 29 | 0.520 |
Why?
|
| Antithrombins | 1 | 2017 | 2 | 0.520 |
Why?
|
| Dabigatran | 1 | 2017 | 5 | 0.520 |
Why?
|
| Antidotes | 1 | 2017 | 3 | 0.520 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 290 | 0.520 |
Why?
|
| Adrenergic Agonists | 1 | 2016 | 4 | 0.510 |
Why?
|
| Pulpitis | 1 | 2016 | 1 | 0.510 |
Why?
|
| Toothache | 1 | 2016 | 1 | 0.510 |
Why?
|
| Naproxen | 1 | 2016 | 1 | 0.510 |
Why?
|
| Amitriptyline | 1 | 2016 | 3 | 0.510 |
Why?
|
| Warfarin | 1 | 2017 | 25 | 0.510 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2016 | 2 | 0.510 |
Why?
|
| Consensus | 6 | 2025 | 81 | 0.510 |
Why?
|
| Reproducibility of Results | 4 | 2025 | 591 | 0.510 |
Why?
|
| Oxycodone | 1 | 2016 | 4 | 0.510 |
Why?
|
| Video-Assisted Surgery | 1 | 2016 | 2 | 0.510 |
Why?
|
| Orthopedic Procedures | 1 | 2019 | 225 | 0.510 |
Why?
|
| Laryngoscopy | 1 | 2016 | 18 | 0.500 |
Why?
|
| Antimicrobial Stewardship | 1 | 2016 | 17 | 0.500 |
Why?
|
| Pregnancy Tests, Immunologic | 1 | 2016 | 1 | 0.500 |
Why?
|
| Global Health | 3 | 2021 | 29 | 0.500 |
Why?
|
| Social Networking | 1 | 2016 | 9 | 0.500 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 83 | 0.500 |
Why?
|
| Central Venous Pressure | 1 | 2016 | 3 | 0.500 |
Why?
|
| Intracranial Pressure | 1 | 2016 | 10 | 0.500 |
Why?
|
| Narcotics | 1 | 2016 | 34 | 0.490 |
Why?
|
| Palpation | 1 | 2016 | 3 | 0.490 |
Why?
|
| Surveys and Questionnaires | 8 | 2025 | 1019 | 0.490 |
Why?
|
| Renal Colic | 1 | 2015 | 1 | 0.480 |
Why?
|
| Urological Agents | 1 | 2015 | 2 | 0.480 |
Why?
|
| Nifedipine | 1 | 2015 | 6 | 0.480 |
Why?
|
| Bronchodilator Agents | 3 | 2022 | 11 | 0.480 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 124 | 0.480 |
Why?
|
| Achievement | 3 | 2022 | 7 | 0.470 |
Why?
|
| Diuretics, Osmotic | 1 | 2015 | 3 | 0.470 |
Why?
|
| Sarcoma, Kaposi | 1 | 2015 | 2 | 0.470 |
Why?
|
| Mannitol | 1 | 2015 | 11 | 0.470 |
Why?
|
| Intracranial Hypertension | 1 | 2015 | 11 | 0.470 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2015 | 42 | 0.460 |
Why?
|
| Needs Assessment | 4 | 2023 | 36 | 0.460 |
Why?
|
| Pain Measurement | 4 | 2018 | 413 | 0.460 |
Why?
|
| Syndrome | 3 | 2021 | 66 | 0.460 |
Why?
|
| Brain Injuries | 1 | 2015 | 31 | 0.450 |
Why?
|
| Doxorubicin | 1 | 2015 | 57 | 0.450 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2014 | 1 | 0.450 |
Why?
|
| Tuberculoma, Intracranial | 1 | 2014 | 1 | 0.450 |
Why?
|
| Ulna Fractures | 1 | 2014 | 7 | 0.450 |
Why?
|
| Paresis | 1 | 2014 | 16 | 0.440 |
Why?
|
| Radius Fractures | 1 | 2014 | 24 | 0.440 |
Why?
|
| Evidence-Based Practice | 3 | 2020 | 53 | 0.440 |
Why?
|
| Lidocaine | 3 | 2023 | 20 | 0.430 |
Why?
|
| Treatment Failure | 3 | 2020 | 126 | 0.430 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 294 | 0.430 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 795 | 0.420 |
Why?
|
| Fatigue | 3 | 2025 | 47 | 0.420 |
Why?
|
| Webcasts as Topic | 2 | 2025 | 2 | 0.410 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 3717 | 0.410 |
Why?
|
| Child, Preschool | 3 | 2021 | 563 | 0.410 |
Why?
|
| Chest Pain | 2 | 2025 | 20 | 0.400 |
Why?
|
| Acute Coronary Syndrome | 2 | 2025 | 10 | 0.400 |
Why?
|
| Vertigo | 2 | 2023 | 6 | 0.390 |
Why?
|
| Liver Cirrhosis | 2 | 2023 | 40 | 0.380 |
Why?
|
| Delphi Technique | 3 | 2025 | 24 | 0.370 |
Why?
|
| Single-Blind Method | 3 | 2017 | 86 | 0.370 |
Why?
|
| Gestational Age | 2 | 2022 | 73 | 0.370 |
Why?
|
| Biomarkers | 4 | 2025 | 477 | 0.360 |
Why?
|
| Pilot Projects | 4 | 2018 | 370 | 0.360 |
Why?
|
| Radiography | 3 | 2022 | 523 | 0.360 |
Why?
|
| Vital Signs | 2 | 2022 | 3 | 0.350 |
Why?
|
| Double-Blind Method | 3 | 2017 | 373 | 0.350 |
Why?
|
| Benzodiazepines | 3 | 2021 | 45 | 0.350 |
Why?
|
| Aspirin | 2 | 2022 | 48 | 0.350 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2025 | 34 | 0.350 |
Why?
|
| Insulin | 2 | 2022 | 77 | 0.350 |
Why?
|
| Analgesics, Opioid | 2 | 2025 | 210 | 0.340 |
Why?
|
| Doxycycline | 2 | 2023 | 14 | 0.340 |
Why?
|
| Mentors | 4 | 2018 | 34 | 0.340 |
Why?
|
| Urinary Bladder | 2 | 2021 | 17 | 0.330 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 534 | 0.330 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 40 | 0.330 |
Why?
|
| Recurrence | 2 | 2021 | 268 | 0.320 |
Why?
|
| Attention | 2 | 2021 | 101 | 0.320 |
Why?
|
| Headache | 2 | 2022 | 36 | 0.320 |
Why?
|
| Shock | 2 | 2021 | 5 | 0.320 |
Why?
|
| Survival Rate | 2 | 2021 | 312 | 0.310 |
Why?
|
| Pediatricians | 2 | 2019 | 3 | 0.310 |
Why?
|
| Prognosis | 4 | 2023 | 714 | 0.300 |
Why?
|
| Fasciotomy | 2 | 2019 | 3 | 0.300 |
Why?
|
| Aggression | 2 | 2021 | 23 | 0.300 |
Why?
|
| Delayed Diagnosis | 2 | 2019 | 10 | 0.300 |
Why?
|
| Creatine Kinase | 2 | 2019 | 19 | 0.300 |
Why?
|
| Learning | 2 | 2020 | 59 | 0.290 |
Why?
|
| Prevalence | 3 | 2025 | 375 | 0.290 |
Why?
|
| Plasma | 2 | 2019 | 13 | 0.280 |
Why?
|
| Streptococcus pyogenes | 2 | 2018 | 4 | 0.280 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2019 | 26 | 0.280 |
Why?
|
| Patient Discharge | 3 | 2023 | 147 | 0.270 |
Why?
|
| Disease Progression | 4 | 2023 | 521 | 0.270 |
Why?
|
| Vasodilator Agents | 2 | 2025 | 28 | 0.260 |
Why?
|
| Clinical Decision-Making | 3 | 2025 | 42 | 0.260 |
Why?
|
| Troponin | 2 | 2025 | 10 | 0.260 |
Why?
|
| Goals | 2 | 2018 | 33 | 0.260 |
Why?
|
| Registries | 5 | 2025 | 173 | 0.260 |
Why?
|
| Administration, Intravenous | 2 | 2024 | 22 | 0.260 |
Why?
|
| Canada | 3 | 2020 | 42 | 0.250 |
Why?
|
| Placebos | 2 | 2016 | 63 | 0.240 |
Why?
|
| Neisseria gonorrhoeae | 2 | 2023 | 3 | 0.240 |
Why?
|
| Chlamydia trachomatis | 2 | 2023 | 5 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 312 | 0.240 |
Why?
|
| Fat Emulsions, Intravenous | 2 | 2022 | 2 | 0.240 |
Why?
|
| Hemorrhage | 2 | 2023 | 73 | 0.240 |
Why?
|
| Thoracentesis | 1 | 2025 | 1 | 0.240 |
Why?
|
| Anatomic Landmarks | 1 | 2025 | 5 | 0.240 |
Why?
|
| Predictive Value of Tests | 4 | 2023 | 438 | 0.230 |
Why?
|
| Efficiency | 1 | 2025 | 20 | 0.230 |
Why?
|
| Patient Portals | 1 | 2025 | 2 | 0.230 |
Why?
|
| Cross-Over Studies | 2 | 2025 | 64 | 0.230 |
Why?
|
| Environmental Monitoring | 1 | 2025 | 9 | 0.230 |
Why?
|
| Air Microbiology | 1 | 2025 | 4 | 0.230 |
Why?
|
| Quality Assurance, Health Care | 1 | 2025 | 29 | 0.230 |
Why?
|
| Respiratory Tract Infections | 1 | 2025 | 23 | 0.230 |
Why?
|
| Bias | 1 | 2025 | 23 | 0.230 |
Why?
|
| Tidal Volume | 2 | 2022 | 9 | 0.230 |
Why?
|
| Patient Participation | 1 | 2025 | 43 | 0.230 |
Why?
|
| Norepinephrine | 1 | 2025 | 28 | 0.230 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2025 | 59 | 0.220 |
Why?
|
| Medicaid | 1 | 2025 | 36 | 0.220 |
Why?
|
| Positive-Pressure Respiration | 1 | 2025 | 7 | 0.220 |
Why?
|
| Binge Drinking | 1 | 2024 | 8 | 0.220 |
Why?
|
| Cost Savings | 1 | 2024 | 29 | 0.220 |
Why?
|
| Diagnostic Imaging | 1 | 2025 | 69 | 0.220 |
Why?
|
| Systole | 1 | 2024 | 12 | 0.220 |
Why?
|
| Heart Failure, Diastolic | 1 | 2024 | 3 | 0.220 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2024 | 3 | 0.220 |
Why?
|
| Diastole | 1 | 2024 | 27 | 0.220 |
Why?
|
| Injections | 2 | 2022 | 42 | 0.220 |
Why?
|
| Contrast Media | 1 | 2024 | 59 | 0.220 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2024 | 41 | 0.220 |
Why?
|
| Referral and Consultation | 1 | 2025 | 82 | 0.220 |
Why?
|
| Sex Factors | 3 | 2021 | 384 | 0.220 |
Why?
|
| Electronic Health Records | 1 | 2025 | 64 | 0.220 |
Why?
|
| Medicare | 1 | 2025 | 106 | 0.220 |
Why?
|
| Spirometry | 2 | 2021 | 9 | 0.220 |
Why?
|
| Animals | 3 | 2022 | 3255 | 0.210 |
Why?
|
| Self Report | 1 | 2025 | 194 | 0.210 |
Why?
|
| Physicians, Women | 2 | 2021 | 15 | 0.210 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2023 | 31 | 0.210 |
Why?
|
| Personal Protective Equipment | 2 | 2020 | 10 | 0.210 |
Why?
|
| Colon, Sigmoid | 1 | 2023 | 11 | 0.210 |
Why?
|
| Chronic Disease | 1 | 2025 | 364 | 0.210 |
Why?
|
| Pleura | 1 | 2023 | 8 | 0.210 |
Why?
|
| Opioid-Related Disorders | 1 | 2025 | 57 | 0.200 |
Why?
|
| Reproductive Rights | 1 | 2023 | 2 | 0.200 |
Why?
|
| Ascites | 1 | 2023 | 2 | 0.200 |
Why?
|
| Ascitic Fluid | 1 | 2023 | 8 | 0.200 |
Why?
|
| Text Messaging | 1 | 2023 | 13 | 0.200 |
Why?
|
| Ebolavirus | 1 | 2023 | 6 | 0.200 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2023 | 7 | 0.200 |
Why?
|
| Health Facilities | 1 | 2023 | 26 | 0.200 |
Why?
|
| Febrile Neutropenia | 1 | 2023 | 1 | 0.200 |
Why?
|
| Electric Countershock | 1 | 2023 | 9 | 0.200 |
Why?
|
| Sexism | 2 | 2021 | 7 | 0.200 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2023 | 5 | 0.200 |
Why?
|
| Relative Value Scales | 1 | 2022 | 4 | 0.200 |
Why?
|
| Pulmonary Ventilation | 1 | 2023 | 7 | 0.200 |
Why?
|
| Medicine | 1 | 2022 | 7 | 0.200 |
Why?
|
| Career Mobility | 2 | 2021 | 13 | 0.200 |
Why?
|
| Fontan Procedure | 1 | 2023 | 12 | 0.200 |
Why?
|
| Hazardous Substances | 1 | 2022 | 2 | 0.190 |
Why?
|
| Injections, Subcutaneous | 1 | 2022 | 21 | 0.190 |
Why?
|
| Observer Variation | 2 | 2025 | 82 | 0.190 |
Why?
|
| Fingers | 1 | 2022 | 8 | 0.190 |
Why?
|
| Lubricants | 1 | 2022 | 1 | 0.190 |
Why?
|
| Albumins | 1 | 2022 | 18 | 0.190 |
Why?
|
| Vitamin K | 1 | 2022 | 5 | 0.190 |
Why?
|
| Prone Position | 1 | 2022 | 25 | 0.190 |
Why?
|
| Pressure | 1 | 2022 | 47 | 0.190 |
Why?
|
| Metoclopramide | 1 | 2022 | 4 | 0.190 |
Why?
|
| Hemoperitoneum | 1 | 2022 | 1 | 0.190 |
Why?
|
| Cardiac Catheterization | 1 | 2022 | 55 | 0.190 |
Why?
|
| Temporomandibular Joint | 1 | 2022 | 16 | 0.190 |
Why?
|
| China | 1 | 2022 | 45 | 0.190 |
Why?
|
| Immunization, Passive | 1 | 2022 | 10 | 0.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 15 | 0.190 |
Why?
|
| Troponin T | 1 | 2022 | 3 | 0.190 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 1412 | 0.190 |
Why?
|
| Pelvis | 1 | 2022 | 23 | 0.190 |
Why?
|
| Elbow | 1 | 2022 | 40 | 0.180 |
Why?
|
| Advanced Cardiac Life Support | 1 | 2022 | 1 | 0.180 |
Why?
|
| Wakefulness | 1 | 2022 | 68 | 0.180 |
Why?
|
| Troponin I | 1 | 2022 | 11 | 0.180 |
Why?
|
| Data Collection | 1 | 2022 | 80 | 0.180 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 20 | 0.180 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 40 | 0.180 |
Why?
|
| ADAMTS13 Protein | 1 | 2021 | 5 | 0.180 |
Why?
|
| Helicobacter pylori | 1 | 2021 | 1 | 0.180 |
Why?
|
| von Willebrand Factor | 1 | 2021 | 11 | 0.180 |
Why?
|
| Language | 1 | 2022 | 57 | 0.180 |
Why?
|
| Patients | 1 | 2021 | 31 | 0.180 |
Why?
|
| Plasma Exchange | 1 | 2021 | 11 | 0.180 |
Why?
|
| Network Meta-Analysis | 1 | 2021 | 22 | 0.180 |
Why?
|
| Electrolytes | 1 | 2021 | 7 | 0.180 |
Why?
|
| Glucose | 1 | 2021 | 43 | 0.180 |
Why?
|
| Pyrroles | 1 | 2021 | 21 | 0.180 |
Why?
|
| Concept Formation | 1 | 2021 | 8 | 0.180 |
Why?
|
| HIV Infections | 2 | 2019 | 430 | 0.180 |
Why?
|
| Vision Disorders | 1 | 2021 | 19 | 0.180 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2021 | 5 | 0.180 |
Why?
|
| Hypnotics and Sedatives | 1 | 2021 | 20 | 0.180 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2021 | 15 | 0.180 |
Why?
|
| Sexual Harassment | 1 | 2021 | 4 | 0.170 |
Why?
|
| Sodium | 1 | 2021 | 44 | 0.170 |
Why?
|
| Cooperative Behavior | 2 | 2022 | 48 | 0.170 |
Why?
|
| Infarction | 1 | 2021 | 19 | 0.170 |
Why?
|
| ROC Curve | 1 | 2021 | 121 | 0.170 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2021 | 17 | 0.170 |
Why?
|
| Breathing Exercises | 1 | 2021 | 3 | 0.170 |
Why?
|
| Peripheral Nerves | 1 | 2021 | 17 | 0.170 |
Why?
|
| Blood Pressure | 1 | 2022 | 166 | 0.170 |
Why?
|
| Respiratory Therapy | 1 | 2021 | 7 | 0.170 |
Why?
|
| Quality of Life | 1 | 2025 | 559 | 0.170 |
Why?
|
| Therapeutic Irrigation | 1 | 2021 | 44 | 0.170 |
Why?
|
| Ludwig's Angina | 1 | 2020 | 1 | 0.170 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 192 | 0.170 |
Why?
|
| Paralysis | 1 | 2021 | 13 | 0.170 |
Why?
|
| Vasoconstriction | 1 | 2020 | 14 | 0.170 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2020 | 5 | 0.170 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 33 | 0.170 |
Why?
|
| Palliative Care | 1 | 2022 | 106 | 0.170 |
Why?
|
| Energy Drinks | 1 | 2020 | 2 | 0.170 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 15 | 0.170 |
Why?
|
| Multiple Organ Failure | 1 | 2020 | 5 | 0.170 |
Why?
|
| Coma | 1 | 2020 | 5 | 0.170 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 162 | 0.170 |
Why?
|
| Role | 1 | 2020 | 7 | 0.170 |
Why?
|
| Chicago | 2 | 2020 | 811 | 0.170 |
Why?
|
| Antimalarials | 1 | 2020 | 8 | 0.170 |
Why?
|
| Adaptation, Physiological | 1 | 2020 | 42 | 0.170 |
Why?
|
| Morbidity | 1 | 2020 | 50 | 0.170 |
Why?
|
| Extremities | 1 | 2020 | 24 | 0.170 |
Why?
|
| Job Satisfaction | 1 | 2020 | 12 | 0.170 |
Why?
|
| Employee Performance Appraisal | 1 | 2020 | 4 | 0.170 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2020 | 1 | 0.170 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 16 | 0.170 |
Why?
|
| Endoscopy | 1 | 2022 | 157 | 0.170 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 38 | 0.170 |
Why?
|
| Academic Performance | 1 | 2020 | 4 | 0.170 |
Why?
|
| Heart Ventricles | 1 | 2021 | 82 | 0.170 |
Why?
|
| Steroids | 1 | 2020 | 21 | 0.170 |
Why?
|
| Computer-Aided Design | 1 | 2020 | 11 | 0.170 |
Why?
|
| Trust | 1 | 2020 | 8 | 0.160 |
Why?
|
| Oxygen Consumption | 1 | 2020 | 52 | 0.160 |
Why?
|
| Caffeine | 1 | 2020 | 51 | 0.160 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2020 | 3 | 0.160 |
Why?
|
| Qualitative Research | 1 | 2020 | 92 | 0.160 |
Why?
|
| Reaction Time | 1 | 2020 | 78 | 0.160 |
Why?
|
| Medical Staff, Hospital | 2 | 2017 | 16 | 0.160 |
Why?
|
| Encephalitis | 1 | 2020 | 10 | 0.160 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2020 | 3 | 0.160 |
Why?
|
| Racism | 1 | 2020 | 24 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 71 | 0.160 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2020 | 8 | 0.160 |
Why?
|
| Splenectomy | 1 | 2020 | 6 | 0.160 |
Why?
|
| Dogs | 1 | 2020 | 139 | 0.160 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2020 | 14 | 0.160 |
Why?
|
| Wound Healing | 1 | 2020 | 107 | 0.160 |
Why?
|
| Schools, Medical | 1 | 2020 | 25 | 0.160 |
Why?
|
| Mentoring | 1 | 2020 | 24 | 0.160 |
Why?
|
| Medical History Taking | 1 | 2020 | 24 | 0.160 |
Why?
|
| Knowledge | 1 | 2020 | 12 | 0.160 |
Why?
|
| Antitubercular Agents | 1 | 2019 | 12 | 0.160 |
Why?
|
| Administration, Intravesical | 1 | 2019 | 5 | 0.160 |
Why?
|
| Abdominal Wall | 1 | 2019 | 6 | 0.160 |
Why?
|
| Travel | 1 | 2019 | 14 | 0.160 |
Why?
|
| Laparotomy | 1 | 2019 | 17 | 0.160 |
Why?
|
| Brain Diseases | 1 | 2020 | 55 | 0.160 |
Why?
|
| Incubators | 1 | 2019 | 1 | 0.160 |
Why?
|
| Melatonin | 1 | 2020 | 91 | 0.160 |
Why?
|
| Delirium | 1 | 2019 | 12 | 0.160 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2019 | 4 | 0.160 |
Why?
|
| Urination Disorders | 1 | 2019 | 7 | 0.160 |
Why?
|
| Sensation Disorders | 1 | 2019 | 9 | 0.160 |
Why?
|
| Bradykinin B2 Receptor Antagonists | 1 | 2019 | 1 | 0.150 |
Why?
|
| Bradykinin | 1 | 2019 | 2 | 0.150 |
Why?
|
| Hypothyroidism | 1 | 2020 | 68 | 0.150 |
Why?
|
| Histamine Antagonists | 1 | 2019 | 2 | 0.150 |
Why?
|
| Histamine | 1 | 2019 | 7 | 0.150 |
Why?
|
| Urticaria | 1 | 2019 | 4 | 0.150 |
Why?
|
| Hip Joint | 1 | 2022 | 241 | 0.150 |
Why?
|
| Organizational Culture | 1 | 2019 | 16 | 0.150 |
Why?
|
| Compression Bandages | 1 | 2019 | 1 | 0.150 |
Why?
|
| Joints | 1 | 2020 | 66 | 0.150 |
Why?
|
| Infant, Newborn | 1 | 2021 | 534 | 0.150 |
Why?
|
| Mortality | 1 | 2019 | 73 | 0.150 |
Why?
|
| Bezoars | 1 | 2019 | 2 | 0.150 |
Why?
|
| Peristalsis | 1 | 2019 | 11 | 0.150 |
Why?
|
| Awards and Prizes | 1 | 2019 | 20 | 0.150 |
Why?
|
| Constriction, Pathologic | 1 | 2019 | 27 | 0.150 |
Why?
|
| Forearm | 1 | 2019 | 18 | 0.150 |
Why?
|
| Aftercare | 1 | 2019 | 22 | 0.150 |
Why?
|
| Myoglobin | 1 | 2019 | 2 | 0.150 |
Why?
|
| Back Pain | 1 | 2019 | 52 | 0.150 |
Why?
|
| Comorbidity | 1 | 2020 | 426 | 0.150 |
Why?
|
| Inflammation | 1 | 2020 | 226 | 0.150 |
Why?
|
| Food | 1 | 2019 | 30 | 0.150 |
Why?
|
| Problem-Based Learning | 1 | 2019 | 7 | 0.150 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 190 | 0.150 |
Why?
|
| Italy | 1 | 2018 | 15 | 0.150 |
Why?
|
| Erythema | 1 | 2018 | 2 | 0.150 |
Why?
|
| France | 1 | 2018 | 13 | 0.150 |
Why?
|
| Administration, Topical | 1 | 2018 | 14 | 0.150 |
Why?
|
| Accreditation | 1 | 2019 | 14 | 0.150 |
Why?
|
| Glucocorticoids | 1 | 2019 | 58 | 0.150 |
Why?
|
| Spinal Cord | 1 | 2019 | 74 | 0.150 |
Why?
|
| Renal Replacement Therapy | 1 | 2019 | 17 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 146 | 0.150 |
Why?
|
| Netherlands | 1 | 2018 | 25 | 0.150 |
Why?
|
| Synovial Fluid | 1 | 2019 | 82 | 0.150 |
Why?
|
| United Kingdom | 1 | 2018 | 40 | 0.150 |
Why?
|
| Cerebrovascular Disorders | 1 | 2020 | 99 | 0.150 |
Why?
|
| Random Allocation | 1 | 2019 | 103 | 0.150 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 64 | 0.150 |
Why?
|
| Peptides | 1 | 2019 | 89 | 0.150 |
Why?
|
| Leg | 1 | 2019 | 40 | 0.150 |
Why?
|
| Oximetry | 1 | 2018 | 10 | 0.150 |
Why?
|
| Societies, Medical | 1 | 2019 | 117 | 0.150 |
Why?
|
| Computer-Assisted Instruction | 1 | 2018 | 18 | 0.140 |
Why?
|
| Bacteremia | 1 | 2019 | 98 | 0.140 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2018 | 3 | 0.140 |
Why?
|
| Social Support | 1 | 2019 | 174 | 0.140 |
Why?
|
| Rickettsia rickettsii | 1 | 2018 | 1 | 0.140 |
Why?
|
| Tick Bites | 1 | 2018 | 1 | 0.140 |
Why?
|
| Ticks | 1 | 2018 | 2 | 0.140 |
Why?
|
| Anesthetics, Dissociative | 1 | 2018 | 2 | 0.140 |
Why?
|
| Heart Valve Prosthesis | 1 | 2018 | 12 | 0.140 |
Why?
|
| Restraint, Physical | 1 | 2018 | 8 | 0.140 |
Why?
|
| Hip Injuries | 1 | 2018 | 7 | 0.140 |
Why?
|
| Urinalysis | 1 | 2018 | 7 | 0.140 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2017 | 6 | 0.140 |
Why?
|
| Intubation | 1 | 2017 | 5 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2018 | 51 | 0.140 |
Why?
|
| Evidence-Based Emergency Medicine | 1 | 2017 | 2 | 0.140 |
Why?
|
| Veins | 1 | 2017 | 8 | 0.140 |
Why?
|
| Bandages | 1 | 2017 | 4 | 0.140 |
Why?
|
| Neck | 1 | 2017 | 23 | 0.140 |
Why?
|
| Dilatation, Pathologic | 1 | 2017 | 4 | 0.140 |
Why?
|
| Antipsychotic Agents | 1 | 2018 | 50 | 0.140 |
Why?
|
| Conscious Sedation | 1 | 2017 | 5 | 0.140 |
Why?
|
| Staphylococcus aureus | 1 | 2018 | 72 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 120 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2018 | 217 | 0.130 |
Why?
|
| Clinical Studies as Topic | 1 | 2017 | 2 | 0.130 |
Why?
|
| Epidemiologic Studies | 1 | 2017 | 17 | 0.130 |
Why?
|
| Biomedical Technology | 1 | 2017 | 4 | 0.130 |
Why?
|
| Cross Infection | 1 | 2020 | 295 | 0.130 |
Why?
|
| Regional Health Planning | 1 | 2017 | 3 | 0.130 |
Why?
|
| Abdominal Pain | 1 | 2017 | 6 | 0.130 |
Why?
|
| Gastroscopy | 1 | 2017 | 9 | 0.130 |
Why?
|
| Administration, Inhalation | 1 | 2017 | 37 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2025 | 311 | 0.130 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2017 | 7 | 0.130 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 9 | 0.130 |
Why?
|
| International Normalized Ratio | 1 | 2017 | 17 | 0.130 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 99 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 120 | 0.130 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2017 | 31 | 0.130 |
Why?
|
| Lumbar Vertebrae | 1 | 2021 | 354 | 0.130 |
Why?
|
| Drug Combinations | 1 | 2016 | 31 | 0.130 |
Why?
|
| Hospitals, Teaching | 1 | 2016 | 28 | 0.130 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2016 | 5 | 0.130 |
Why?
|
| Laboratories, Hospital | 1 | 2016 | 3 | 0.130 |
Why?
|
| Intraocular Pressure | 1 | 2016 | 8 | 0.120 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 151 | 0.120 |
Why?
|
| Appendectomy | 1 | 2016 | 13 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 122 | 0.120 |
Why?
|
| X-Rays | 1 | 2016 | 6 | 0.120 |
Why?
|
| Stroke Volume | 1 | 2016 | 41 | 0.120 |
Why?
|
| Staphylococcal Infections | 1 | 2018 | 156 | 0.120 |
Why?
|
| Early Diagnosis | 1 | 2016 | 50 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2016 | 225 | 0.120 |
Why?
|
| Liposomes | 1 | 2015 | 13 | 0.120 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 24 | 0.120 |
Why?
|
| Feasibility Studies | 1 | 2015 | 210 | 0.110 |
Why?
|
| Infection Control | 3 | 2020 | 168 | 0.110 |
Why?
|
| Illinois | 1 | 2014 | 221 | 0.110 |
Why?
|
| Motivation | 2 | 2025 | 82 | 0.100 |
Why?
|
| Shoulder Joint | 1 | 2018 | 513 | 0.100 |
Why?
|
| Hospitals | 2 | 2025 | 157 | 0.100 |
Why?
|
| Disease Outbreaks | 2 | 2023 | 76 | 0.100 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 4 | 0.080 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 8 | 0.080 |
Why?
|
| Antigen Presentation | 1 | 2010 | 14 | 0.080 |
Why?
|
| HIV-1 | 1 | 2010 | 202 | 0.070 |
Why?
|
| Credentialing | 1 | 2025 | 5 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 1 | 2025 | 23 | 0.060 |
Why?
|
| Genome, Viral | 1 | 2025 | 9 | 0.060 |
Why?
|
| Employment | 1 | 2025 | 38 | 0.060 |
Why?
|
| Paraspinal Muscles | 1 | 2025 | 2 | 0.060 |
Why?
|
| Radiation Exposure | 1 | 2024 | 5 | 0.060 |
Why?
|
| Monte Carlo Method | 1 | 2024 | 36 | 0.060 |
Why?
|
| Radiation Dosage | 1 | 2024 | 35 | 0.060 |
Why?
|
| Carbon Monoxide Poisoning | 1 | 2024 | 2 | 0.060 |
Why?
|
| Decompression Sickness | 1 | 2024 | 3 | 0.060 |
Why?
|
| Retinal Artery Occlusion | 1 | 2024 | 3 | 0.060 |
Why?
|
| Embolism, Air | 1 | 2024 | 10 | 0.060 |
Why?
|
| Bupivacaine | 1 | 2025 | 39 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2025 | 152 | 0.050 |
Why?
|
| Respiratory Sounds | 1 | 2023 | 5 | 0.050 |
Why?
|
| Peer Review, Research | 1 | 2022 | 8 | 0.050 |
Why?
|
| Metoprolol | 1 | 2022 | 5 | 0.050 |
Why?
|
| Africa, Western | 1 | 2022 | 2 | 0.050 |
Why?
|
| Diltiazem | 1 | 2022 | 7 | 0.050 |
Why?
|
| Monkeypox virus | 1 | 2022 | 2 | 0.050 |
Why?
|
| Anesthesia, Local | 1 | 2022 | 6 | 0.050 |
Why?
|
| Heart Rate | 1 | 2022 | 103 | 0.050 |
Why?
|
| Lipids | 1 | 2022 | 44 | 0.050 |
Why?
|
| Therapies, Investigational | 1 | 2022 | 5 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2022 | 25 | 0.050 |
Why?
|
| Pulmonary Atelectasis | 1 | 2021 | 3 | 0.040 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 2021 | 3 | 0.040 |
Why?
|
| Coronary Angiography | 1 | 2021 | 68 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2022 | 481 | 0.040 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2020 | 2 | 0.040 |
Why?
|
| Piracetam | 1 | 2020 | 7 | 0.040 |
Why?
|
| Exercise Test | 1 | 2021 | 112 | 0.040 |
Why?
|
| North America | 1 | 2020 | 32 | 0.040 |
Why?
|
| Safety Management | 1 | 2020 | 11 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2020 | 34 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 55 | 0.040 |
Why?
|
| Mental Status Schedule | 1 | 2019 | 66 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2020 | 110 | 0.040 |
Why?
|
| Phenotype | 1 | 2019 | 255 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2019 | 158 | 0.040 |
Why?
|
| Research | 1 | 2018 | 36 | 0.040 |
Why?
|
| Internet | 1 | 2019 | 77 | 0.040 |
Why?
|
| Crowding | 1 | 2017 | 1 | 0.030 |
Why?
|
| Workflow | 1 | 2017 | 7 | 0.030 |
Why?
|
| Personal Space | 1 | 2017 | 4 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 2017 | 24 | 0.030 |
Why?
|
| Friends | 1 | 2017 | 5 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 30 | 0.030 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2017 | 32 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 107 | 0.030 |
Why?
|
| Urban Population | 1 | 2017 | 127 | 0.030 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 6 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 17 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 14 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 12 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 10 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 40 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 62 | 0.020 |
Why?
|
| Viral Load | 1 | 2010 | 70 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 70 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2010 | 54 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 164 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 152 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 168 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 350 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 111 | 0.020 |
Why?
|